Actively Recruiting
Evaluating HB0056 Injection for Adults with Moderate to Severe Asthma Randomized, Double-Blind, Placebo-Controlled Study of Safety and Effectiveness
Led by Shanghai Huaota Biopharmaceutical Co., Ltd. · Updated on 2026-10-28
160
Participants Needed
2
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the drug HB0056 for treating adults with moderate to severe asthma. This clinical trial aims to find out if HB0056 reduces the need for rescue inhalers and to assess the safety of this medication. The study includes adults aged 18 to 75 years with a history of asthma and ongoing treatment with inhaled corticosteroids and other asthma control drugs. The study has two parts Part I tests different doses of HB0056 compared to a placebo in a randomized, double-blind design to evaluate safety, drug behavior in the body, immune response, and early signs of effectiveness. Part II further explores the best dosing schedules of HB0056 for moderate to severe asthma and continues safety monitoring. Participants receive HB0056 or placebo injections either every two or four weeks. Participants will keep a diary to record symptoms and rescue inhaler use while attending regular visits for lung function tests, asthma control questionnaires, and monitoring for side effects. The study measures lung function changes, asthma exacerbations, quality of life, and immune responses over periods up to 56 weeks. Safety and antibody development are closely observed throughout the trial.
CONDITIONS
Brief Title
A Study of HB0056 in Adult Participants With Moderate to Severe Asthma
Research Team
J
Jingjing Wang
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here